Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward

Research output: Contribution to journalReview article

Abstract

Recent advances in the treatment of pediatric tumors led to an improvement of survival in this population. As a result, many pediatric survivors experience long-term effects that impact their quality of life. Therefore, it is extremely important to identify new treatment approaches that may target the tumor minimizing the drug-related side effects. Over the past 10 years, remarkable advances in nanomedicine have provided several potential tools for cancer treatment. Recently, there has been a growing interest towards therapeutic nanocarriers in the pediatric field, since they represent a new strategy to enhance the drug efficacy and reduce the toxicity. Various nanoformulations have been developed to improve the targeting and the release of antitumor compound to cancer cells in pediatric tumors and clinical trials have been conducted or are ongoing. Exosomes are nanometer-sized vesicles that play a crucial role in mediating intercellular communication. Thanks to to their intrinsic cell targeting properties, stability in the circulation, and bio-compatibility, they are emerging as new promising vehicles both for drugs and biological therapeutics. Moreover, these nanovesicles are a reservoir of potential diagnostic and prognostic markers. In this review, we describe recent advances in the treatment of pediatric tumors through nanodelivery system with particular attention to neuroblastoma, soft-tissues/bone sarcomas and pediatric brain tumors. Furthermore, we explore the potential role of exosomes as an effective option of nanodelivery providing insights into their characteristics in pediatric tumors and their use in adult clinical trials.

Original languageEnglish
Pages (from-to)1328-1343
Number of pages16
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume17
Issue number10
DOIs
Publication statusPublished - 2017

Fingerprint

Pediatrics
Neoplasms
Exosomes
Therapeutics
Clinical Trials
Nanomedicine
Drug-Related Side Effects and Adverse Reactions
Neuroblastoma
Brain Neoplasms
Sarcoma
Pharmaceutical Preparations
Survivors
Quality of Life
Survival
Population

Keywords

  • Antineoplastic Agents/chemistry
  • Cell Proliferation/drug effects
  • Child
  • Drug Delivery Systems
  • Drug Screening Assays, Antitumor
  • Humans
  • Nanomedicine
  • Neoplasms/drug therapy

Cite this

@article{6d3b8aded479478bb2482a663460387c,
title = "Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward",
abstract = "Recent advances in the treatment of pediatric tumors led to an improvement of survival in this population. As a result, many pediatric survivors experience long-term effects that impact their quality of life. Therefore, it is extremely important to identify new treatment approaches that may target the tumor minimizing the drug-related side effects. Over the past 10 years, remarkable advances in nanomedicine have provided several potential tools for cancer treatment. Recently, there has been a growing interest towards therapeutic nanocarriers in the pediatric field, since they represent a new strategy to enhance the drug efficacy and reduce the toxicity. Various nanoformulations have been developed to improve the targeting and the release of antitumor compound to cancer cells in pediatric tumors and clinical trials have been conducted or are ongoing. Exosomes are nanometer-sized vesicles that play a crucial role in mediating intercellular communication. Thanks to to their intrinsic cell targeting properties, stability in the circulation, and bio-compatibility, they are emerging as new promising vehicles both for drugs and biological therapeutics. Moreover, these nanovesicles are a reservoir of potential diagnostic and prognostic markers. In this review, we describe recent advances in the treatment of pediatric tumors through nanodelivery system with particular attention to neuroblastoma, soft-tissues/bone sarcomas and pediatric brain tumors. Furthermore, we explore the potential role of exosomes as an effective option of nanodelivery providing insights into their characteristics in pediatric tumors and their use in adult clinical trials.",
keywords = "Antineoplastic Agents/chemistry, Cell Proliferation/drug effects, Child, Drug Delivery Systems, Drug Screening Assays, Antitumor, Humans, Nanomedicine, Neoplasms/drug therapy",
author = "Marta Colletti and Paolo, {Virginia Di} and Angela Galardi and Milano, {Giuseppe Maria} and Angela Mastronuzzi and Franco Locatelli and {Di Giannatale}, Angela",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2017",
doi = "10.2174/1871520617666170103101141",
language = "English",
volume = "17",
pages = "1328--1343",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Nano-Delivery in Pediatric Tumors

T2 - Looking Back, Moving Forward

AU - Colletti, Marta

AU - Paolo, Virginia Di

AU - Galardi, Angela

AU - Milano, Giuseppe Maria

AU - Mastronuzzi, Angela

AU - Locatelli, Franco

AU - Di Giannatale, Angela

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2017

Y1 - 2017

N2 - Recent advances in the treatment of pediatric tumors led to an improvement of survival in this population. As a result, many pediatric survivors experience long-term effects that impact their quality of life. Therefore, it is extremely important to identify new treatment approaches that may target the tumor minimizing the drug-related side effects. Over the past 10 years, remarkable advances in nanomedicine have provided several potential tools for cancer treatment. Recently, there has been a growing interest towards therapeutic nanocarriers in the pediatric field, since they represent a new strategy to enhance the drug efficacy and reduce the toxicity. Various nanoformulations have been developed to improve the targeting and the release of antitumor compound to cancer cells in pediatric tumors and clinical trials have been conducted or are ongoing. Exosomes are nanometer-sized vesicles that play a crucial role in mediating intercellular communication. Thanks to to their intrinsic cell targeting properties, stability in the circulation, and bio-compatibility, they are emerging as new promising vehicles both for drugs and biological therapeutics. Moreover, these nanovesicles are a reservoir of potential diagnostic and prognostic markers. In this review, we describe recent advances in the treatment of pediatric tumors through nanodelivery system with particular attention to neuroblastoma, soft-tissues/bone sarcomas and pediatric brain tumors. Furthermore, we explore the potential role of exosomes as an effective option of nanodelivery providing insights into their characteristics in pediatric tumors and their use in adult clinical trials.

AB - Recent advances in the treatment of pediatric tumors led to an improvement of survival in this population. As a result, many pediatric survivors experience long-term effects that impact their quality of life. Therefore, it is extremely important to identify new treatment approaches that may target the tumor minimizing the drug-related side effects. Over the past 10 years, remarkable advances in nanomedicine have provided several potential tools for cancer treatment. Recently, there has been a growing interest towards therapeutic nanocarriers in the pediatric field, since they represent a new strategy to enhance the drug efficacy and reduce the toxicity. Various nanoformulations have been developed to improve the targeting and the release of antitumor compound to cancer cells in pediatric tumors and clinical trials have been conducted or are ongoing. Exosomes are nanometer-sized vesicles that play a crucial role in mediating intercellular communication. Thanks to to their intrinsic cell targeting properties, stability in the circulation, and bio-compatibility, they are emerging as new promising vehicles both for drugs and biological therapeutics. Moreover, these nanovesicles are a reservoir of potential diagnostic and prognostic markers. In this review, we describe recent advances in the treatment of pediatric tumors through nanodelivery system with particular attention to neuroblastoma, soft-tissues/bone sarcomas and pediatric brain tumors. Furthermore, we explore the potential role of exosomes as an effective option of nanodelivery providing insights into their characteristics in pediatric tumors and their use in adult clinical trials.

KW - Antineoplastic Agents/chemistry

KW - Cell Proliferation/drug effects

KW - Child

KW - Drug Delivery Systems

KW - Drug Screening Assays, Antitumor

KW - Humans

KW - Nanomedicine

KW - Neoplasms/drug therapy

U2 - 10.2174/1871520617666170103101141

DO - 10.2174/1871520617666170103101141

M3 - Review article

C2 - 28044936

VL - 17

SP - 1328

EP - 1343

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 10

ER -